Endometrial Cancer: Awareness and Equity

CE / CME

Improving Provider Awareness About Healthcare Equity: Improving All Patients’ Access to Care in Endometrial Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 15, 2023

Expiration: June 14, 2024

Activity

Progress
1
Course Completed

Introduction

Despite exciting advances in the field of gynecology oncology, underrepresented patients of color disproportionally face barriers to optimal/equitable care for endometrial cancer. Moreover, data also suggest that many providers caring for patients with endometrial cancer are unaware of the disparities in their field. Recognizing and raising awareness of factors contributing to inequities is an important first step in improving care for all women with endometrial cancer to help overcome these barriers to care. 

In this module, Shannon N. Westin, MD, MPH, reviews and discusses key factors leading to inequitable care for endometrial cancer and proposes strategies to overcome them with guideline-concordant care. This module is part of  a larger educational program tasked with raising awareness and sharing expert’s strategies for improving outcomes for all women with gynecologic cancer. 

Please note that the slide thumbnails in this activity link to PowerPoint slidesets that also can be found here, each focused on the specific gynecologic topic of interest. These slidesets also may be downloaded by clicking on any of the thumbnails within the activity. 

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: Once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a healthcare professional (HCP) providing patient care, how many patients with endometrial cancer do you see in a typical month?

Presurvey

Your patient has a history of high-risk serous endometrial cancer and previously received treatment with platinum-based chemotherapy. A pathology report of new lung metastases during chemotherapy confirmed endometrial cancer and showed a P53 mutation and MSH6 protein loss by immunohistochemistry. No alteration in HER2 was detected.

In your current practice, which of the following treatments would you consider to be the optimal choice for this patient?

Your patient with advanced stage IV endometrial cancer has a partial response to her first-line carboplatin regimen. She currently is not a candidate for surgery. She asks you about any oral treatments that might help her take part in a bucket list trip with her family. You mention that she might consider taking part in the ongoing phase III XPORT-EC clinical trial evaluating selinexor, a first-in-class oral selective inhibitor of nuclear export, vs placebo.

As you plan therapy for this patient and take into account her preferences, what should you consider next to see if a trial with selinexor might be a good option for her?

You recently saw data presented for the phase III ENGOT-EN6/GOG-3031/RUBY trial, evaluating carboplatin and paclitaxel with or without dostarlimab followed by dostarlimab or placebo maintenance for 3 years in patients with primary advanced or recurrent endometrial cancer. Which of the following patient populations saw the most PFS benefit with the addition of dostarlimab to standard of care chemotherapy?